Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesManagement of head and neck cancer in elderly patients
Drugs & Aging, 08/12/09
Lalami Y et al. – In a review of the management of head and neck cancer (HNC) in elderly pts, it was concluded that once all physiological and biological risk factors have been addressed, a large proportion of geriatric pts can and should be offered the same HNC treatment as is offered to younger pts.
Methods- HNC represents a heterogeneous group of tumours requiring multimodality approaches.
- It is debatable whether HNC treatment in geriatric pts should be different to that delivered for younger pts.
- Risk of death seems to be higher in HNC pts with higher co-morbidity status.
- Despite the fact that there is no significant difference in outcome in younger vs older pts, older HNC pts are more likely to receive nonstandard, less aggressive therapies than younger pts.
- Age alone should not be the basis for selecting treatment options in older HNC pts.
- A thorough pretreatment evaluation of co-morbidities should always be performed, and radical surgical options should not be excluded in older HNC pts treated with curative intent, as postoperative complications occur no more frequently in older pts than in younger pts.
- Locoregional control and disease-free survival in older pts treated with radiation therapy are comparable to the results seen in younger HNC pts, with the same acute toxicity profile.
- In pts receiving systemic therapies, special attention must be given to modification of chemotherapy dosages according to renal and hepatic function.
- Molecular-targeted therapies appear to be very useful in such pts because of their favourable tolerability.
Related Articles
Cessation of alcohol drinking, tobacco smoking and the reversal of head and neck cancer risk
International Journal of Epidemiology, 10/08/09
Relevance Score: 84%
Planned neck dissection following primary chemoradiation for advanced-stage head and neck cancer
Otolaryngology Head and Neck Surgery, 10/13/09
Relevance Score: 83%
Extracts from The Cochrane Library: Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer
Otolaryngology Head and Neck Surgery, 10/12/09
Relevance Score: 83%
Clinical Features and Short-Term Outcome of Critically Ill Patients With Head and Neck Cancer in the Medical Intensive Care Unit
American Journal of Clinical Oncology, 10/07/09
Relevance Score: 83%
Sheddase Activity of Tumor Necrosis Factor-alpha Converting Enzyme Is Increased and Prognostically Valuable in Head and Neck Cancer
Cancer Epidemiology, Biomarkers & Prevention, 10/27/09
Relevance Score: 82%
Today in Head and Neck...keeping you current
Receive free subspecialty "5-minute updates" via email
Radiation Treatment Interruptions Greater Than One Week and Low Hemoglobin Levels (12 g/dL) are Predictors of Local Regional Failure After Definitive Concurrent Chemotherapy and Intensity-Modulated Radiation Therapy for Squamous Cell Carcinoma of the Head and Neck
American Journal of Clinical Oncology, 12/07/09
Failure to Diagnose and Delayed Diagnosis of Cancer
The Journal of the American Dental Association , 12/07/09
Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma
BMC Cancer, 12/04/09
Sponsor
Article Search
Sponsor
Sponsor